Aya Mohamed | MSc, MD 🎗· @Dr_Oncologista · X·· 2 days agoScore90
Body
HORIZON-Breast06:
Trastuzumab Rezetecan in HER2-Low Metastatic #BreastCancer — A Major PFS Benefit, With OS and Long-Term Safety Requiring Further Follow-Up
@OncoAlert #ESMO26 @myESMO #Bcsm
670 views · 28 likes · 11 reposts · 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: Aya Mohamed | MSc, MD 🎗 · x.com